References

EFFICACY OF FEXOFENDADINE COMPARED TO ORAL ANTIHISTAMINES AVAILABLE OVER THE COUNTER IN AUSTRALIA. JANUARY 2021.

  1. Hindmarch, I., and Z. Shamsi. “Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side‐effects.” Clinical & Experimental Allergy 29 (1999): 133-142.
  2. Hindmarch, I., Z. Shamsi, and S. Kimber. “An evaluation of the effects of high‐dose fexofenadine on the central nervous system: a double‐blind, placebo‐controlled study in healthy volunteers.” Clinical & Experimental Allergy 32.1 (2002): 133-139.
  3. Howarth, P. H. “The choice of an H1‐antihistamine for the 21st century.” Clinical & Experimental Allergy Reviews 2.1 (2002): 18-25.
  4. Mason, J., R. Reynolds, and N. Rao. “The systemic safety of fexofenadine HCl.” Clinical & Experimental Allergy 29 (1999): 163-170.
  5. Tashiro, Manabu, et al. “Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1‐receptor occupancy using 11C‐doxepin positron emission tomography.” The Journal of Clinical Pharmacology 44.8 (2004): 890-900.
  6. Tashiro, Manabu, et al. “Effects of fexofenadine and hydroxyzine on brake reaction time during car‐driving with cellular phone use.” Human Psychopharmacology: Clinical and Experimental 20.7 (2005): 501-509.
  7. Vaccchiano, Charles, et al. “Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude.” Aviation, space, and environmental medicine 79.8 (2008): 754-760.
  8. Amichai, Boaz, Marcelo H. Grunwald, and Lesley Brenner. “Fexofenadine hydrochloride–a new anti-histaminic drug.” The Israel Medical Association journal: IMAJ 3.3 (2001): 207.
  9. Muliol, J., M. Maurer, and J. Bousquet. “Sleep and allergic rhinitis.” J Investig Allergol Clin Immunol 18.6 (2008): 415-9.
  10. Hampel, Frank, et al. “Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis.” Annals of Allergy, Asthma & Immunology 91.4 (2003): 354-361.
  11. Kawauchi, Hideyuki, et al. “Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties.” International Journal of Molecular Sciences 20.1 (2019): 213.
  12. Kamei, Hiroyuki, et al. “Comparative study of acute effects of single doses of fexofenadine, olopatadine, d‐chlorpheniramine and placebo on psychomotor function in healthy volunteers.” Human Psychopharmacology: Clinical and Experimental 18.8 (2003): 611-618.
  13. Day, James Halliday, et al. “Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit.” Annals of Allergy, Asthma & Immunology 79.6 (1997): 533-540.
  14. Van Cauwenberge, Paul, and E. F. Juniper. “Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.” Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology 30.6 (2000): 891.
  15. Casale, Thomas B., Carolyn Andrade, and Roger Qu. “Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.” Allergy and asthma proceedings. Vol. 20. No. 3. OceanSide Publications, 1999.
  16. Bachert, Claus. “A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.” Clinical therapeutics 31.5 (2009): 921-944.
  17. Lehman, J & Blaiss, M. “Selecting the Optimal Oral Antihistamine for Patients with Allergic Rhinitis”. Therapy in Practice 66.18: 2309-2319.
  18. Greisner, W. A. “Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines”. Allergy Asthma Proc. 25.2 (2004): 81-83
  19. Simons, F. E. R & Simons, K.J. “Histamins and H1-antihistamines: Celebrating a century of progress”. Clnical review in allergy and immunology 128.6 (2011): 1139-1150
  20. Telfast Prescribing Information, CMI, ANZ

Purchase now from selected retailers

The liability of the Company or of SANOFI shall not be incurred by a third party site that can be accessed via the Site. We do not have any way of controlling the content of such third party sites which remain entirely independent of the Company. Moreover, the existence of a link between the Site and a third party site does not under any circumstances mean that the Company approves the content of that site in any way whatsoever and in particular the use that may be made of it.

Contact Us

If you’d like to know which product might be suitable for your needs, or if you have questions relating to any of our products, please fill in the form below. We’d love to hear from you. To speak with a team member or report an adverse event, please call 1800 818 806 within Australia.

Thank you for your submission. A representative will be in contact shortly.